These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27177227)

  • 21. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
    Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
    Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice.
    Hichami A; Yessoufou A; Ghiringhelli F; Salvadori F; Moutairou K; Zwetyenga N; Khan NA
    Biochimie; 2016 Dec; 131():1-10. PubMed ID: 27613402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
    Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
    Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.
    Fushimi T; Kojima A; Moore MA; Crystal RG
    J Clin Invest; 2000 May; 105(10):1383-93. PubMed ID: 10811846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids.
    Ziske C; Etzrodt PE; Eliu AS; Gorschlüter M; Strehl J; Flieger D; Messmer D; Schmitz V; Gonzalez-Carmona MA; Sievers E; Brossart P; Sauerbruch T; Schmidt-Wolf IG
    Pancreas; 2009 Oct; 38(7):758-65. PubMed ID: 19546834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
    Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model.
    Kwilas AR; Ardiani A; Dirmeier U; Wottawah C; Schlom J; Hodge JW
    Oncotarget; 2015 Sep; 6(29):28194-210. PubMed ID: 26317648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
    Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J
    Immunology; 2007 Feb; 120(2):148-59. PubMed ID: 17274112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
    Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
    Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.
    Wang W; Ma Y; Li J; Shi HS; Wang LQ; Guo FC; Zhang J; Li D; Mo BH; Wen F; Liu T; Liu YT; Wang YS; Wei YQ
    Gene Ther; 2013 Oct; 20(10):970-8. PubMed ID: 23636245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
    Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
    Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
    Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
    Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
    Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
    Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient.
    Siddiqui I; Erreni M; van Brakel M; Debets R; Allavena P
    J Immunother Cancer; 2016; 4():21. PubMed ID: 27096098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.